Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Secukinumab safe, effective for moderate-to-severe plaque psoriasis

15 Jul 2019

Secukinumab is safe and effective for the treatment of moderate-to-severe plaque psoriasis, with effects lasting up to a year after treatment initiation, reports a recent study.

A total of 158 patients (mean age, 28±17.7 years; 57 percent male) were included in the multicentre, prospective, observational study. All patients presented with moderate-to-severe plaque psoriasis and received secukinumab. Follow-ups were conducted every 12 weeks for 52 weeks.

More than a third (34.8 percent; n=55) of the participants had psoriatic arthritis, while 41.8 percent (n=66) and 34.2 percent (n=54) were smokers and drinkers, respectively. Almost half (44.9 percent; n=71) had body mass index >30 kg/cm2 and were characterized as obese.

After 52 weeks, majority (82.9 percent; n=131) of the patients were still on secukinumab and only 27 (17.1 percent) had discontinued treatment. Reasons for discontinuation included lack of efficacy (n=8), loss of efficacy (n=15) and loss to follow-up (n=4).

At week 4, 57 percent of the participants achieved 75-percent reduction in their baseline scores in the Psoriasis Area and Severity Index (PASI). This grew to 83.5 percent and 89 percent at weeks 12 and 24, respectively, before dropping back down to 78.5 percent by week 52.

In comparison, 27.8 percent achieved a 90-percent drop in their baseline PASI scores (PASI-90) by week 4, growing to 62 percent and 64.6 percent by weeks 12 and 24. PASI-90 was at 63.2 percent at the end of the intervention period.

Only 28 participants (17.7 percent) experienced adverse events over the course of the study, the most common of which were headaches and nasopharyngitis (n=9 each; 5.7 percent). Hypertension (n=6; 3.8 percent), oral candidiasis (n=5; 3.2 percent) and diarrhoea (n=2; 1.3 percent) were other such events.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.